Despite a market bloodbath that left the S&P 500 down 4.84%, Vertex Pharmaceuticals managed a modest gain of 0.11%, flaunting resilience. The biotech firm outpaced the broader medical sector over the ...
Vertex Pharmaceuticals has analysts doing financial backflips as they boost its price targets, with Royal Bank of Canada ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback